XML 55 R72.htm IDEA: XBRL DOCUMENT v2.4.0.8
Quarterly Financial Information (Unaudited) (Details) (USD $)
 3 Months Ended 12 Months Ended
Dec. 31, 2013
Sep. 30, 2013
Jun. 30, 2013
Mar. 31, 2013
Dec. 31, 2012
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Quarterly Financial Information Disclosure [Abstract]                      
Revenue under collaborative research and development arrangements $ 822,217 $ 8,388,760 $ 14,311 $ 14,259 $ 14,296 $ 22,495 $ 20,907 $ 24,838 $ 9,239,547 $ 82,536 $ 156,397
Revenue under collaborative research and development arrangements with affiliated entity 106,250 106,250 106,250 106,250 142,483 222,484 106,250 106,250 425,000 577,467 411,459
Grants and miscellaneous revenue 811,199 991,835 665,049 1,334,716 977,974 609,717 308,925 1,562,033 3,802,799 3,458,649 9,227,401
Total revenues 1,739,666 9,486,845 785,610 1,455,225 1,134,753 854,696 436,082 1,693,121 13,467,346 4,118,652 9,795,257
Research and development 6,404,005 5,438,405 4,411,082 5,115,112 4,442,841 4,972,319 4,527,086 4,042,579 21,368,604 17,984,825 20,032,001
General and administrative 4,339,539 3,282,796 3,046,586 2,974,153 2,919,000 2,674,362 2,696,909 2,488,088 13,643,074 10,778,359 11,988,796
Gain on sale of assets (1,000,000) 0 (1,000,000) 0 0 (500,000) 0 (651,000) (2,000,000) (1,151,000) (587,000)
Total operating expenses 9,743,544 8,721,201 6,457,668 8,089,265 7,361,841 7,146,681 7,223,995 5,879,667 33,011,678 27,612,184 31,433,797
Loss from operations (8,003,878) 765,644 (5,672,058) (6,634,040) (6,227,088) (6,291,985) (6,787,913) (4,186,546) (19,544,332) (23,493,532) (21,638,540)
Interest and other income, net 8,576 46,787 37,391 39,460 56,520 37,013 41,036 31,544 132,214 166,113 34,285
Change in fair value of common stock warrants (6,052,965) (34,952,210) (3,199,878) (1,427,616) 3,049,649 (1,113,638) 3,594,782 (3,548,173) (45,632,669) 1,982,620 8,690,658
(Loss) Gain from investment in affiliated entity (1,419,536) 3,248,926 (2,032,051) (836,084) 2,449,615 736,121 (992,373) (561,544) (1,038,745) 1,631,819 (2,390,498)
Net loss (15,467,803) (30,890,853) (10,866,596) (8,858,280) (671,304) (6,632,489) (4,144,468) (8,264,719) (66,083,532) (19,712,980) (15,304,095)
Net loss attributable to non-controlling interest 13,473 13,443 14,008 14,160 12,553 10,413 11,289 9,770 55,084 44,025 51,150
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (15,454,330) $ (30,877,410) $ (10,852,588) $ (8,844,120) $ (658,751) $ (6,622,076) $ (4,133,179) $ (8,254,949) $ (66,028,448) $ (19,668,955) $ (15,252,945)
Net loss attributable to Inovio Pharmaceuticals, Inc. stockholders (In dollars per share) $ (0.07) $ (0.16) $ (0.06) $ (0.06) $ 0.00 $ (0.05) $ (0.03) $ (0.06) $ (0.36) $ (0.14) $ (0.12)
Weighted average number of common shares—basic and diluted (In shares) 208,509,676 191,956,155 179,954,816 156,155,532 140,704,889 135,389,308 134,968,394 134,968,394 184,351,090 136,509,247 126,239,336